Company
Humans are the heart of our research.
With this motto in mind, FBM-PHARMA GmbH focuses on the production and development of personalized medicine based on autologous substances. This includes complementary medicine therapies in the treatment of autoimmune diseases as well as autologous serum eye drops in the treatment of various eye diseases.
Our focus is on therapies for atopic diseases such as neurodermatitis, psoriasis, eczemas as well as chronic inflammatory diseases of the lung and the respiratory tract such as bronchial asthma. This includes chronic inflammatory diseases of the gastrointestinal tract such as Crohn’s disease as well as allergies and diseases of the rheumatic spectrum.
As diverse as the clinical picture is, as diverse are the factors leading to an autoimmune disease. The manifestation for each autoimmune disease is different for each patient and therefore the treatment differs from patient to patient.
With the combination of the scientific aspects of classical immunology and our experience in naturopathic-based medicine, FBM-PHARMA GmbH has developed their individual immunotherapeutics. The individual immunotherapies are immunomodulatory therapies with the aim to rebalance the unbalanced immune system. By strengthening the body's defenses the body should be stimulated to perform self-regeneration. This way, dysregulation of the immune system can be counteracted. The focus is on the causal therapy approach.
- 1995: Establishment of FBM-PHARMA GmbH
- 1996: Preparations undertaken for a retrospective study on AHIT® in patients with neurodermatitis in collaboration with the University Hospital in Mannheim under the supervision of Prof. Dr. med. Ernst Jung
- 1997: Start of the controlled study at the University Hospital in Mannheim under the supervision of Prof. Dr. med. Ernst Jung
- 1998: Based on findings that have been obtained from the treatment of neurodermatitis, FBM-PHARMA GMBH develops the cosmetic care product DAOSAN® to treat dry skin.
- 2001: Extension of the AHIT® concept with the introduction of AHIT®-S
- 2002: The DAOSAN® line is expanded with the introduction of DAOSAN®Plus and DAOSAN® body milk
- 2003: Extension of the AHIT® concept with the introduction of AHIT®-CA
- 2006: Establishment of FBM Holding AG in Zurich, expansion of our investor base to finance further expansion of FBM-PHARMA GmbH and expand research and development activities
- 2006: Completion of the controlled study
- 2007: Extension of the AHIT concept with the introduction of AHIT®-SL
- 2010: Renaming of FBM Holding AG to Vaccentis AG
- 2012: Extension of the AHIT® concept with the introduction of urexent®, formerly known as AHIT® Infant
- 2014: Reissue of the DAOSAN® cream and body lotion
- 2017: Implementation of the superior denotation “individual immunotherapy” for all autologous forms of therapy of FBM-PHARMA GmbH
- 2020: Production of DAOSAN®, cream and body lotion was ceased.
We look for individualised solutions to restore your health. The continuous development of patient-specific therapies and a traditionally high quality awareness are a matter of fact for us. Our goal is to offer physicians and patients alternative methods of being cured by breaking new ground. We feel directly responsible for the patient and pursue his / her development by direct contact with him / her and his / her supervising therapist.
High-quality products and individual therapy regimens are the pillars of this special form of the individual immunotherapy. We want to offer sick people full-scale treatment with well-tolerated drugs.
Close cooperation with trusted therapists using different therapies ensures patients the best possible care whose recovery is our main focus.
The huge amount of positive feedback from our patients is a daily incentive to continue to work with great commitment for the recovery of sick people.
With our forms of therapy, we want to contribute to the fight against the constant increase of allergic and autoimmune diseases. In this regard, activating the self-healing powers of each patient by means of our drugs comes first.
A sensible combination of scientific knowledge in immunology and the experience of naturopathy, it is our endeavour to help many patients gently achieves a higher quality of life with well-tolerated drugs.
To carry out our vision, we focus on the research and development of other forms of therapies to treat additional disease patterns with the individual immunotherapy.
The individual immunotherapeutics are all prepared at our company site in Ludwigshafen / Rhine. FBM-PHARMA GmbH has an EU manufacturing permit for the preparations of drugs using one's own blood and urine and is subject to guidelines for drug-producing plants. Compliance with and continuous optimisation of our quality standards in the fields of drug preparation and corporate management, which are regularly revised by the relevant state authority, are a matter of course.
We meet the highest standards during the preparation of each individual drug. Production in qualified clean rooms and the use of qualified and continuously trained employees guarantee the patient's optimal safety for obtaining a high quality product. Due to the autologous (patient's own) nature of the source materials (blood, plasm and urine) as well as the individual preparation and bottling process, the production of the drugs is exclusively done manually.
All source materials necessary for the production process are quality-tested before use. The production process itself takes place according to the strictly-controlled principles of the drug industry that apply to the preparation of parenterals (sterile preparations for injection) and, in particular, parenterals from blood products. Facilities, equipment and processes must always reflect the current state of science and technology.
Extensive final checks ensure a product that meets the highest requirements in terms of quality and microbiological parameters.
For special production conditions, computerised logistics have been developed so as to ensure that the source materials and finished products of each individual patient can be tracked at any time from entry to delivery through the use of digital codes.
Our employees identify themselves with the company. Their motivation and their own initiative ensure the continuous progress of FBM-PHARMA GmbH. Team spirit and reliability have a positive effect on the working atmosphere.
Patient safety is our top priority. Permanent training and the continued optimisation of our processes are important components of our quality management system.